SCREENING FOR AGENTS AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS

NIH GUIDE, Volume 21, Number 22, June 12, 1992



RFP AVAILABLE:  NCI-CM-37818-28



P.T. 34



Keywords:

  AIDS 

  Screening of Drugs/Agents 

  Antivirals 

  Cell Lines 



National Cancer Institute



The National Cancer Institute (NCI), Division of Cancer Treatment,

Developmental Therapeutics Program,  Antiviral Evaluations Branch, is

seeking an organization to provide assistance in the primary screening

of experimental agents utilizing the HTLV/LAV (human AIDS virus).  An

organization is sought that will supply the necessary equipment,

personnel, and facilities to conduct screening on the scale of 20,000

tests per year.  The tasks will include maintaining and expanding one

or more cell lines and the virus necessary to infect these cells, the

preparation of experimental agents for testing, and the collection and

submission of data.  The project will primarily involve cell culture,

although approximately 20 percent of the work will involve in vitro

detailed agent testing, and less than 10 percent  of the work will

involve in vivo testing with murine leukemia virus.



It is anticipated that one cost-reimbursement contract, completion

form, will be awarded as a result of the solicitation.  This contract

is planned to be incrementally funded over a five-year period.  The

proposed contract project represents a recompetition of Southern

Research Institute, N01-CM-87237.



Because of the nature of work involving live human immunodeficiency

virus (HIV), offerors must show evidence at the time of the best and

final offer that P-3 level biocontainment facilities are available for

use on this project.



This project requires that the following restriction be applied.  "The

NCI signs legally binding agreements with certain suppliers (often

pharmaceutical or chemical companies) that state that all information

on compounds submitted by the supplier will be held confidential.  The

successful offeror will be expected to test such commercially

confidential (discreet) agents.  The NCI believes that the compound

cannot be sent to potential competitors of the supplier, and thus

pharmaceutical and chemical companies must be excluded from the

competition.  For purposes of this exclusion, a pharmaceutical or

chemical company is defined as an organization that manufactures and/or

sells drugs and chemicals to the general public for profit."



All responsible sources may submit a proposal that shall be considered

by the NCI.  This announcement is not a Request for Proposals (RFP).

RFP No. NCI-CM-37818-28 will be available on or about June 12, 1992,

with a response date of July 27, 1992, for the receipt of proposals.

All copies of the RFP may be obtained by written request to:



Ms. Carolyn Barker

Contract Specialist, Research Contracts Branch

Treatment Contracts Section

Executive Plaza South, Room 603

9000 Rockville Pike

Bethesda, MD  20892



No collect calls will be accepted.



.

Return to 1992 Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.